Regulation of matrix remodeling by peroxisome proliferator-activated receptor-γ: A novel link between metabolism and fibrogenesis

Open Rheumatology Journal

Volumn 6, Issue 1, 2012, Pages 103-115

  Wei, Jun ^a   Bhattacharyya, Swati ^a   Jain, Manu ^a   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

PPAR ; SPPARM; Systemic sclerosis; TGF

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ANTIFIBROTIC AGENT; BORTEZOMIB; CHEMOKINE; CYTOKINE; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TROGLITAZONE; WNT PROTEIN;

ADIPOGENESIS; AMINO TERMINAL SEQUENCE; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME REPRESSION; EPIGENETICS; FIBROGENESIS; FIBROSIS; GENE EXPRESSION REGULATION; GENETIC MANIPULATION; GLUCOSE HOMEOSTASIS; HEART MUSCLE FIBROSIS; HUMAN; INSULIN SENSITIVITY; LIVER FIBROSIS; LUNG FIBROSIS; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; WNT SIGNALING PATHWAY;

EID: 84863946574     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901206010103     Document Type: Review

References (136)

1. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systematic sclerosis shfting paradigms, emerging oppertunities. Nat Rev Rheumatol 2011; 8: 54.
2. Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 2007; 9(2): 136-43.
3. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79(7): 1147-56.
4. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123(6): 993-9.
5. Wei J, Bhattacharyya S, Varga J. Peroxisome proliferator-activated receptor gamma: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol 2010; 22(6): 671-6.
6. McKenna NJ, Cooney AJ, DeMayo FJ, et al. Minireview: Evolution of NURSA, the Nuclear Receptor Signaling Atlas. Mol Endocrinol 2009; 23(6): 740-6.
7. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10(4): 355-61.
8. Zhu Y, Qi C, Korenberg JR, et al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA 1995; 92(17): 7921-5.
9. Luconi M, Cantini G, Serio M. Peroxisome proliferator-activated receptor gamma (PPARgamma): is the genomic activity the only answer? Steroids 2010; 75(8-9): 585-94.
10. Garcia-Bates TM, Lehmann GM, Simpson-Haidaris PJ, Bernstein SH, Sime PJ, Phipps RP. Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. PPAR Res 2008; 2008: 834612.
11. Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, Sime PJ. The Role of PPARs in Lung Fibrosis. PPAR Res 2007; 2007: 71323.
12. Wei J, Ghosh AK, Sargent JL, et al. PPARgamma downregulation by TGFss in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010; 5(11): e13778.
13. Zheng S, Chen A. Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2007; 292(1): G113-23.
14. Kintscher U, Wakino S, Bruemmer D, et al. TGF-beta(1) induces peroxisome proliferator-activated receptor gamma1 and gamma2 expression in human THP-1 monocytes. Biochem Biophys Res Commun 2002; 297(4): 794-9.
15. Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM, Bulun SE. Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction. Cancer Res 2001; 61(5): 2250-5.
16. Yamasaki S, Nakashima T, Kawakami A, et al. Cytokines regulate fibroblast-like synovial cell differentiation to adipocyte-like cells. Rheumatology 2004; 43(4): 448-52.
17. Tanaka SS, Kojima Y, Yamaguchi YL, Nishinakamura R, Tam PP. Impact of WNT signaling on tissue lineage differentiation in the early mouse embryo. Dev Growth Differ 2011; 53(7): 843-56.
18. Ross SE, Hemati N, Longo KA, et al. Inhibition of adipogenesis by Wnt signaling. Science 2000; 289(5481): 950-3.
19. Takada I, Mihara M, Suzawa M, et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 2007; 9(11): 1273-85.
20. Takada I, Suzawa M, Matsumoto K, Kato S. Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts. Ann N Y Acad Sci 2007; 1116: 182-95.
21. Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD, Macdougald OA. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem 2007; 282(19): 14515-24.
22. Wu Z, Bucher NL, Farmer SR. Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol Cell Biol 1996; 16(8): 4128-36.
23. Jimenez MA, Akerblad P, Sigvardsson M, Rosen ED. Critical role for Ebf1 and Ebf2 in the adipogenic transcriptional cascade. Mol Cell Biol 2007; 27(2): 743-57.
24. Waki H, Park KW, Mitro N, et al. The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. Cell Metab 2007; 5(5): 357-70.
25. Park KW, Waki H, Villanueva CJ, et al. Inhibitor of DNA binding 2 is a small molecule-inducible modulator of peroxisome proliferator-activated receptor-gamma expression and adipocyte differentiation. Mol Endocrinol 2008; 22(9): 2038-48.
26. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47: 89-116.
27. Liby K, Hock T, Yore MM, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 2005; 65(11): 4789-98.
28. Cho HY, Gladwell W, Wang X, et al. Nrf2-regulated PPAR{gamma} expression is critical to protection against acute lung injury in mice. Am J Respir Crit Care Med 2010; 182(2): 170-82.
29. Abdelkarim M, Caron S, Duhem C, et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J Biol Chem 2010; 285(47): 36759-67.
30. Okamura M, Kudo H, Wakabayashi K, et al. COUP-TFII acts downstream of Wnt/beta-catenin signal to silence PPARgamma gene expression and repress adipogenesis. Proc Natl Acad Sci USA 2009; 106(14): 5819-24.
31. Bhattacharyya S, Wu M, Fang F, Tourtellotte W, Feghali-Bostwick C, Varga J. Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy. Matrix Biol 2011; 30(4): 235-42.
32. Fu M, Zhang J, Lin Y, Zhu X, Ehrengruber MU, Chen YE. Early growth response factor-1 is a critical transcriptional mediator of peroxisome proliferator-activated receptor-gamma 1 gene expression in human aortic smooth muscle cells. J Biol Chem 2002; 277(30): 26808-14.
33. Boyle KB, Hadaschik D, Virtue S, et al. The transcription factors Egr1 and Egr2 have opposing influences on adipocyte differentiation. Cell Death Differ 2009; 16(5): 782-9.
34. Tsukamoto H, She H, Hazra S, Cheng J, Miyahara T. Antiadipogenic regulation underlies hepatic stellate cell transdifferentiation. J Gastroenterol Hepatol 2006; 21 (Suppl 3): S102-5.
35. Mann J, Chu DC, Maxwell A, et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010; 138(2): 705-14, 714 e1-4.
36. Zhu NL, Wang J, Tsukamoto H. The Necdin-Wnt pathway causes epigenetic peroxisome proliferator-activated receptor gamma repression in hepatic stellate cells. J Biol Chem 2010; 285(40): 30463-71.
37. Noer A, Sorensen AL, Boquest AC, Collas P. Stable CpG hypomethylation of adipogenic promoters in freshly isolated, cultured, and differentiated mesenchymal stem cells from adipose tissue. Mol Biol Cell 2006; 17(8): 3543-56.
38. Fujiki K, Kano F, Shiota K, Murata M. Expression of the peroxisome proliferator activated receptor gamma gene is repressed by DNA methylation in visceral adipose tissue of mouse models of diabetes. BMC Biol 2009; 7: 38.
39. Kim SY, Kim AY, Lee HW, et al. miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARgamma expression. Biochem Biophys Res Commun 2010; 392(3): 323-8.
40. Karbiener M, Fischer C, Nowitsch S, et al. microRNA miR-27b impairs human adipocyte differentiation and targets PPARgamma. Biochem Biophys Res Commun 2009; 390(2): 247-51.
41. Yun Z, Maecker HL, Johnson RS, Giaccia AJ, Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell 2002; 2(3): 331-41.
42. Simon MF, Daviaud D, Pradere JP, et al. Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferatoractivated receptor gamma2. J Biol Chem 2005; 280(15): 14656-62.
43. Tan JT, McLennan SV, Song WW, et al. Connective tissue growth factor inhibits adipocyte differentiation. Am J Physiol Cell Physiol 2008; 295(3): C740-51.
44. Zhou Y, Jia X, Qin J, et al. Leptin inhibits PPARgamma gene expression in hepatic stellate cells in the mouse model of liver damage. Mol Cell Endocrinol 2010; 323(2): 193-200.
45. Gong K, Xing D, Li P, et al. Hypoxia Induces Downregulation of PPAR{gamma} in Isolated Pulmonary Arterial Smooth Muscle Cells and in Rat Lung via Transforming Growth Factor-{beta} Signaling. Am J Physiol Lung Cell Mol Physiol 2011; 301(6): L8899-901.
46. Ajuwon KM, Spurlock ME. Adiponectin inhibits LPS-induced NFkappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 2005; 288(5): R1220-5.
47. Van Beekum O, Fleskens V, Kalkhoven E. Posttranslational modifications of PPAR-gamma: fine-tuning the metabolic master regulator. Obesity 2009; 17(2): 213-9.
48. Burns KA, Vanden HJP. Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 2007; 1771(8): 952-60.
49. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 1996; 274(5295): 2100-3.
50. Choi JH, Banks AS, Estall JL, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010; 466(7305): 451-6.
51. Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM. Degradation of the peroxisome proliferatoractivated receptor gamma is linked to ligand-dependent activation. J Biol Chem 2000; 275(24): 18527-33.
52. Floyd ZE, Stephens JM. Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J Biol Chem 2002; 277(6): 4062-8.
53. Juge-Aubry C, Pernin A, Favez T, et al. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5'-flanking region. J Biol Chem 1997; 272(40): 25252-9.
54. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2(10): 748-59.
55. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43(4): 527-50.
56. McIntyre TM, Pontsler AV, Silva AR, et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci USA 2003; 100(1): 131-6.
57. Giaginis C, Giagini A, Theocharis S. Peroxisome proliferatoractivated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis. Pharmacol Res 2009; 60(3): 160-9.
58. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11): 1106-18.
59. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008; 68(15): 2131-62.
60. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med, 2011. 365(4): 327-36.
61. Wang Y, Porter WW, Suh N, et al. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol 2000; 14(10): 1550-6.
62. Higgins LS, Depaoli AM. Selective peroxisome proliferatoractivated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 2010; 91(1): 267S-72S.
63. Choi JH, Banks AS, Kamenecka TM, et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature, 2011; 477: 477-81.
64. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008; 77: 289-312.
65. Sugawara A, Uruno A, Kudo M, Matsuda K, Yang CW, Ito S. Effects of PPARgamma on hypertension, atherosclerosis, and chronic kidney disease. Endocr J 2010; 57(10): 847-52.
66. Wan Y. PPARgamma in bone homeostasis. Trends Endocrinol Metab 2010; 21(12): 722-8.
67. Jeninga EH, Gurnell M, Kalkhoven E. Functional implications of genetic variation in human PPARgamma. Trends Endocrinol Metab 2009; 20(8): 380-7.
68. Agostini M, Schoenmakers E, Mitchell C, et al. Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab 2006; 4(4): 303-11.
69. Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4(4): 585-95.
70. Hansmann G, de Jesus Perez VA, Alastalo TP, et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008; 118(5): 1846-57.
71. Guignabert C, Alvira CM, Alastalo TP, et al. Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol 2009; 297(6): L1082-90.
72. Kang BY, Kleinhenz JM, Murphy TC, Hart CM. The PPAR{gamma} Ligand, Rosiglitazone, Attenuates Hypoxia-Induced Endothelin Signaling In Vitro and In Vivo. Am J Physiol Lung Cell Mol Physiol 2011; 301: L881-91.
73. Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999; 4(4): 611-7.
74. Fleischmajer R, Damiano V, Nedwich A. Alteration of subcutaneous tissue in systemic scleroderma. Arch Dermatol 1972; 105(1): 59-66.
75. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 2009; 174(2): 519-33.
76. Zheng F, Fornoni A, Elliot SJ, et al. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 2002; 282(4): F639-48.
77. Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferatoractivated receptors and hepatic stellate cell activation. J Biol Chem 2000; 275(46): 35715-22.
78. Culver DA, Barna BP, Raychaudhuri B, et al. Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 2004; 30(1): 1-5.
79. Karnik P, Tekeste Z, McCormick TS, et al. Hair follicle stem cellspecific PPARgamma deletion causes scarring alopecia. J Invest Dermatol 2009; 129(5): 1243-57.
80. Yang L, Chan CC, Kwon OS, et al. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2006; 291(5): G902-11.
81. Kis A, Murdoch C, Zhang M, et al. Defective peroxisomal proliferators activated receptor gamma activity due to dominantnegative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice. Eur J Heart Fail 2009; 11(6): 533-41.
82. Kapoor M, McCann M, Liu S, et al. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009; 60(9): 2822-9.
83. Ghosh AK, Wei J, Wu M, Varga J. Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptorgamma. Biochem Biophys Res Commun 2008; 374(2): 231-6.
84. Wei J, Melichian D, Komura K, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum 2011; 63(6): 1707-17.
85. Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ, Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology 2010; 49(2): 259-63.
86. Sargent JL, Milano A, Bhattacharyya S, et al. A TGFbetaresponsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010; 130(3): 694-705.
87. Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009; 30(5): 234-9.
88. Arakawa H, Jinnin M, Muchemwa FC, et al. Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients. Exp Dermatol 2011; 20(9): 764-6.
89. Lakota K, Wei J, Carns M, et al. Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? Arthritis Res Ther 2012; 14(3): R102.
90. Bogatkevich GS, Highland KB, Akter T, Silver RM. The PPAR agonist rosiglitazone is antifibrotic for scleroderma lung fibroblasts: mechanisms of action and differential racial effects. Pulm Med 2012; 2012: 545172.
91. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004; 50(4): 1305-18.
92. Burgess HA, Daugherty LE, Thatcher TH, et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005; 288(6): L1146-53.
93. Marra F, Efsen E, Romanelli RG, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000; 119(2): 466-78.
94. Tan X, Dagher H, Hutton CA, Bourke JE. Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res 2010; 11: 21.
95. Milam JE, Keshamouni VG, Phan SH, et al. PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294(5): L891-901.
96. Aoki Y, Maeno T, Aoyagi K, et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration 2009; 77(3): 311-9.
97. Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC. PPAR-alpha and-gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 2006; 21(9): 2399-405.
98. Kiss E, Popovic ZV, Bedke J, et al. Peroxisome proliferatoractivated receptor (PPAR)gamma can inhibit chronic renal allograft damage. Am J Pathol 2010; 176(5): 2150-62.
99. Yoshihara D, Kurahashi H, Morita M, et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 2011; 300(2): F465-74.
100. Iglarz M, Touyz RM, Viel EC, et al. Peroxisome proliferatoractivated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003; 42(4): 737-43.
101. Maejima Y, Okada H, Haraguchi G, et al. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest 2011; 91(6): 932-44.
102. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzymealtered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2004; 315(1): 187-95.
103. Uto H, Nakanishi C, Ido A, et al. The peroxisome proliferatoractivated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a cholinedeficient, l-amino acid-defined diet. Hepatol Res 2005; 32(4): 235-42.
104. Genovese T, Cuzzocrea S, Di Paola R, et al. Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J 2005; 25(2): 225-34.
105. Honda K, Marquillies P, Capron M, Dombrowicz D. Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol 2004; 113(5): 882-8.
106. Jain M, Budinger GR, Lo A, et al. Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting peroxisome proliferator-activated receptor-gamma. Am J Respir Crit Care Med 2011; 183(11): 1490-8.
107. Kapoor M, Kojima F, Qian M, Yang L, Crofford LJ. Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway. J Biol Chem 2007; 282(8): 5356-66.
108. McCann MR, Monemdjou R, Ghassemi-Kakroodi P, et al. mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Res Ther 2011; 13(1): R6.
109. Mutlu GM, Budinger GR, Wu M, et al. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-{beta}1 signalling. Thorax 2011; 67: 139-46.
110. Varga J, Whitfield ML. Transforming growth factor-beta in systemic sclerosis (scleroderma). Front Biosci (Schol Ed). 2009; 1: 226-35.
111. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5(4): 200-6.
112. Ghosh AK, Bhattacharyya S, Wei J, et al. Peroxisome proliferatoractivated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 2009; 23(9): 2968-77.
113. Ghosh AK, Varga J. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol 2007; 213(3): 663-71.
114. Reka AK, Kurapati H, Narala VR, et al. Peroxisome proliferatoractivated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 2010; 9(12): 3221-32.
115. Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 2006; 350(2): 385-91.
116. Hong KM, Belperio JA, Keane MP, Burdick MD, Strieter RM. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferatoractivated receptor gamma. J Biol Chem 2007; 282(31): 22910-20.
117. Wu M, Melichian DS, de la Garza M, et al. Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. Am J Pathol 2009; 175(3): 1041-55.
118. De Backer O, Elinck E, Priem E, Leybaert L, Lefebvre RA. Peroxisome proliferator-activated receptor gamma activation alleviates postoperative ileus in mice by inhibition of Egr-1 expression and its downstream target genes. J Pharmacol Exp Ther 2009; 331(2): 496-503.
119. Li Y, Wen X, Spataro BC, Hu K, Dai C, Liu Y. hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 2006; 17(1): 54-65.
120. Handy JA, Fu P, Kumar P, et al. Adiponectin inhibits leptin signaling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J 2011; 440: 385-95.
121. Wanninger J, Neumeier M, Bauer S, et al. Adiponectin induces the transforming growth factor decoy receptor BAMBI in human hepatocytes. FEBS Lett 2011; 585(9): 1338-44.
122. Shafiei MS, Shetty S, Scherer PE, Rockey DC. Adiponectin regulation of stellate cell activation via PPARgamma-dependent and-independent mechanisms. Am J Pathol 2011; 178(6): 2690-9.
123. Lee SJ, Yang EK, Kim SG. Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation. Mol Pharmacol 2006; 70(1): 415-25.
124. White ES, Atrasz RG, Hu B, et al. Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med 2006; 173(1): 112-21.
125. Bu S, Asano Y, Bujor A, Highland K, Hant F, Trojanowska M. Dihydrosphingosine 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels. Arthritis Rheum 2010; 62(7): 2117-26.
126. Kuwano K. PTEN as a new agent in the fight against fibrogenesis. Am J Respir Crit Care Med 2006; 173(1): 5-6.
127. Kulkarni AA, Thatcher TH, Olsen KC, Maggirwar SB, Phipps RP, Sime PJ. PPAR-gamma ligands repress TGFbeta-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PLoS One 2011; 6(1): e15909.
128. Lam AP, Gottardi CJ. Beta-catenin signaling: a novel mediator of fibrosis and potential therapeutic target. Curr Opin Rheumatol 2011; 23(6): 562-7.
129. Bergmann C, Akhmetshina A, Dees C, et al. Inhibition of glycogen synthase kinase 3{beta} induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis 2011; 70: 2191-8.
130. Wei J, Fang F, Lam AP, et al. Wnt/-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 2012; doi: 10.1002/art.3442.
131. Gustafson B, Eliasson B, Smith U. Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis. Diabetologia 2010; 53(3): 536-40.
132. Lu D, Carson DA. Repression of beta-catenin signaling by PPAR gamma ligands. Eur J Pharmacol 2010; 636(1-3): 198-202.
133. Ameshima S, Golpon H, Cool CD, et al. Peroxisome proliferatoractivated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 2003; 92(10): 1162-9.
134. Nisbet RE, Bland JM, Kleinhenz DJ, et al. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol 2010; 42(4): 482-90.
135. Hansmann G, Zamanian RT. PPARgamma activation: a potential treatment for pulmonary hypertension. Sci Transl Med 2009; 1(12): 12ps14.
136. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457-71.